Tessara Therapeutics
Sydney, Australia· Est.
A platform company delivering 3‑D human brain models for accelerated CNS drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A platform company delivering 3‑D human brain models for accelerated CNS drug discovery.
NeurologyAlzheimer's diseaseCNS disorders
Technology Platform
RealBrain® uses a proprietary synthetic hydrogel matrix to support iPSC‑derived neural stem cells that self‑organise into functional 3‑D micro‑tissues, enabling scalable, high‑throughput CNS disease modelling.
Opportunities
Rising demand for human‑relevant CNS models and regulatory pressure to reduce animal testing create a strong market for Tessara’s scalable 3‑D neural platforms.
Risk Factors
Early‑stage technology adoption, reliance on partnership contracts for revenue, and the need for sustained funding to expand disease models and scale manufacturing.
Competitive Landscape
Competes with organoid and micro‑physiological system providers such as Emulate, Hologene, and StemCell Technologies; differentiation lies in its proprietary hydrogel matrix, standardized micro‑tissue format, and integrated high‑throughput screening capability.